[News] BGJ398 for FGFR-altered advanced cholangiocarcinoma

Results from a single-arm, multicentre, phase 2 trial suggest that patients with advanced cholangiocarcinoma with genetic alterations in fibroblast growth factor receptor (FGFR) might respond to treatment with BGJ398, a first-in-class selective pan-FGFR kinase inhibitor.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: News Source Type: research